Business
PDMR Dealings
PDMR Dealings.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \nRNS Number : 5353G Faron Pharmaceuticals Oy 06 November 2018 \n\n \nFaron Pharmaceuticals Oy\n\n(\"Faron\" or the \"Company\")\n \nPDMR Dealings \n \n \nTURKU - FINLAND, 6 November 2018 - Faron Pharmaceuticals Ltd (\"Faron\") (LON: FARN), the clinical stage biopharmaceutical company, announces that on 6 November 2018 it was notified of the following PDMR dealing.\n \nOn 26 October 2018, Dr Matti Karvonen, VP Drug Development, Chief Medical Officer of Faron, had acquired 20,000 ordinary shares in Faron at a price of 82.90 pence per ordinary share.\n \nThe notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.\n \nThis announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (\"MAR\"). \n \n\n\n\nNotification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014\n\n\n\n\n1\n\n\nDetails of the person discharging managerial responsibilities/person closely associated\n\n\n\n\na.\n\n\nName\n\n\nMatti Karvonen\n\n\n\n\n2\n\n\nReason for notification\n\n\n \n \n \n\n\n\n\na.\n\n\nPosition/Status\n\n\nPerson discharging managerial responsibilities - VP Drug Development, Chief Medical Officer\n\n\n\n\nb.\n\n\nInitial notification/\nAmendment\n\n\nInitial Notification\n\n\n\n\n3\n\n\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\n\n\n\n\na.\n\n\nName\n\n\nFaron Pharmaceuticals Oy \n\n\n\n\nb.\n\n\nLEI\n\n\n7437009H31TO1DC0EB42\n\n\n\n\n4\n\n\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n\n\n\n\na.\n\n\nDescription of the financial instrument, type of instrument\n\nIdentification Code\n\n\nOrdinary shares\n\nISIN: FI4000153309\n\n\n\n\...